CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM
4.1 Overview
4.1.1 Market size and forecast
4.2 Tablets
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Others
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
CHAPTER 5: IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL
5.1 Overview
5.1.1 Market size and forecast
5.2 Hospital Pharmacies
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Drug stores and Retail Pharmacies
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
5.4 Online Providers
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market share analysis by country
CHAPTER 6: IODINE DEFICIENCY DRUG MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Dosage Form
6.2.3 North America Market size and forecast, by Distribution Channel
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Key market trends, growth factors and opportunities
6.2.4.1.2 Market size and forecast, by Dosage Form
6.2.4.1.3 Market size and forecast, by Distribution Channel
6.2.4.2 Canada
6.2.4.2.1 Key market trends, growth factors and opportunities
6.2.4.2.2 Market size and forecast, by Dosage Form
6.2.4.2.3 Market size and forecast, by Distribution Channel
6.2.4.3 Mexico
6.2.4.3.1 Key market trends, growth factors and opportunities
6.2.4.3.2 Market size and forecast, by Dosage Form
6.2.4.3.3 Market size and forecast, by Distribution Channel
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Dosage Form
6.3.3 Europe Market size and forecast, by Distribution Channel
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Key market trends, growth factors and opportunities
6.3.4.1.2 Market size and forecast, by Dosage Form
6.3.4.1.3 Market size and forecast, by Distribution Channel
6.3.4.2 France
6.3.4.2.1 Key market trends, growth factors and opportunities
6.3.4.2.2 Market size and forecast, by Dosage Form
6.3.4.2.3 Market size and forecast, by Distribution Channel
6.3.4.3 UK
6.3.4.3.1 Key market trends, growth factors and opportunities
6.3.4.3.2 Market size and forecast, by Dosage Form
6.3.4.3.3 Market size and forecast, by Distribution Channel
6.3.4.4 Italy
6.3.4.4.1 Key market trends, growth factors and opportunities
6.3.4.4.2 Market size and forecast, by Dosage Form
6.3.4.4.3 Market size and forecast, by Distribution Channel
6.3.4.5 Spain
6.3.4.5.1 Key market trends, growth factors and opportunities
6.3.4.5.2 Market size and forecast, by Dosage Form
6.3.4.5.3 Market size and forecast, by Distribution Channel
6.3.4.6 Rest of Europe
6.3.4.6.1 Key market trends, growth factors and opportunities
6.3.4.6.2 Market size and forecast, by Dosage Form
6.3.4.6.3 Market size and forecast, by Distribution Channel
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Dosage Form
6.4.3 Asia-Pacific Market size and forecast, by Distribution Channel
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Key market trends, growth factors and opportunities
6.4.4.1.2 Market size and forecast, by Dosage Form
6.4.4.1.3 Market size and forecast, by Distribution Channel
6.4.4.2 China
6.4.4.2.1 Key market trends, growth factors and opportunities
6.4.4.2.2 Market size and forecast, by Dosage Form
6.4.4.2.3 Market size and forecast, by Distribution Channel
6.4.4.3 India
6.4.4.3.1 Key market trends, growth factors and opportunities
6.4.4.3.2 Market size and forecast, by Dosage Form
6.4.4.3.3 Market size and forecast, by Distribution Channel
6.4.4.4 Australia
6.4.4.4.1 Key market trends, growth factors and opportunities
6.4.4.4.2 Market size and forecast, by Dosage Form
6.4.4.4.3 Market size and forecast, by Distribution Channel
6.4.4.5 South Korea
6.4.4.5.1 Key market trends, growth factors and opportunities
6.4.4.5.2 Market size and forecast, by Dosage Form
6.4.4.5.3 Market size and forecast, by Distribution Channel
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Key market trends, growth factors and opportunities
6.4.4.6.2 Market size and forecast, by Dosage Form
6.4.4.6.3 Market size and forecast, by Distribution Channel
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Dosage Form
6.5.3 LAMEA Market size and forecast, by Distribution Channel
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Key market trends, growth factors and opportunities
6.5.4.1.2 Market size and forecast, by Dosage Form
6.5.4.1.3 Market size and forecast, by Distribution Channel
6.5.4.2 Saudi Arabia
6.5.4.2.1 Key market trends, growth factors and opportunities
6.5.4.2.2 Market size and forecast, by Dosage Form
6.5.4.2.3 Market size and forecast, by Distribution Channel
6.5.4.3 South Africa
6.5.4.3.1 Key market trends, growth factors and opportunities
6.5.4.3.2 Market size and forecast, by Dosage Form
6.5.4.3.3 Market size and forecast, by Distribution Channel
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Key market trends, growth factors and opportunities
6.5.4.4.2 Market size and forecast, by Dosage Form
6.5.4.4.3 Market size and forecast, by Distribution Channel
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Abbott Laboratories
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Abbvie Inc
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 Cipla Ltd
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Fresenius SE and Co. KGaA
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Glaxosmithkline plc
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Lupin Ltd
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Macleods Pharmaceuticals Ltd
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Merck KGaA
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Pfizer Inc.
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Teva Pharmaceutical Industries Ltd.
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
TABLE 1. GLOBAL IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 2. IODINE DEFICIENCY DRUG MARKET FOR TABLETS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. IODINE DEFICIENCY DRUG MARKET FOR TABLETS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. IODINE DEFICIENCY DRUG MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. IODINE DEFICIENCY DRUG MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 6. GLOBAL IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 7. IODINE DEFICIENCY DRUG MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 8. IODINE DEFICIENCY DRUG MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 9. IODINE DEFICIENCY DRUG MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. IODINE DEFICIENCY DRUG MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 11. IODINE DEFICIENCY DRUG MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. IODINE DEFICIENCY DRUG MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 13. IODINE DEFICIENCY DRUG MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. NORTH AMERICA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 15. NORTH AMERICA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 16. NORTH AMERICA IODINE DEFICIENCY DRUG MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 17. U.S. IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 18. U.S. IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 19. CANADA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 20. CANADA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 21. MEXICO IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 22. MEXICO IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 23. EUROPE IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 24. EUROPE IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 25. EUROPE IODINE DEFICIENCY DRUG MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 26. GERMANY IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 27. GERMANY IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 28. FRANCE IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 29. FRANCE IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 30. UK IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 31. UK IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 32. ITALY IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 33. ITALY IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 34. SPAIN IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 35. SPAIN IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 36. REST OF EUROPE IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 37. REST OF EUROPE IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 38. ASIA-PACIFIC IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 39. ASIA-PACIFIC IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 40. ASIA-PACIFIC IODINE DEFICIENCY DRUG MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 41. JAPAN IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 42. JAPAN IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 43. CHINA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 44. CHINA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 45. INDIA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 46. INDIA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 47. AUSTRALIA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 48. AUSTRALIA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 49. SOUTH KOREA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 50. SOUTH KOREA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 51. REST OF ASIA-PACIFIC IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 52. REST OF ASIA-PACIFIC IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 53. LAMEA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 54. LAMEA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 55. LAMEA IODINE DEFICIENCY DRUG MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 56. BRAZIL IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 57. BRAZIL IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 58. SAUDI ARABIA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 59. SAUDI ARABIA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 60. SOUTH AFRICA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 61. SOUTH AFRICA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 62. REST OF LAMEA IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM, 2021-2031 (REVENUE, $MILLION)
TABLE 63. REST OF LAMEA IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 64.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 65.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 66.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 67.ABBOTT LABORATORIES: NET SALES
TABLE 68.ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 69.ABBVIE INC: COMPANY SNAPSHOT
TABLE 70.ABBVIE INC: OPERATING SEGMENTS
TABLE 71.ABBVIE INC: PRODUCT PORTFOLIO
TABLE 72.ABBVIE INC: NET SALES
TABLE 73.ABBVIE INC: KEY STRATERGIES
TABLE 74.CIPLA LTD: COMPANY SNAPSHOT
TABLE 75.CIPLA LTD: OPERATING SEGMENTS
TABLE 76.CIPLA LTD: PRODUCT PORTFOLIO
TABLE 77.CIPLA LTD: NET SALES
TABLE 78.CIPLA LTD: KEY STRATERGIES
TABLE 79.FRESENIUS SE AND CO. KGAA: COMPANY SNAPSHOT
TABLE 80.FRESENIUS SE AND CO. KGAA: OPERATING SEGMENTS
TABLE 81.FRESENIUS SE AND CO. KGAA: PRODUCT PORTFOLIO
TABLE 82.FRESENIUS SE AND CO. KGAA: NET SALES
TABLE 83.FRESENIUS SE AND CO. KGAA: KEY STRATERGIES
TABLE 84.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 85.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 86.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 87.GLAXOSMITHKLINE PLC: NET SALES
TABLE 88.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 89.LUPIN LTD: COMPANY SNAPSHOT
TABLE 90.LUPIN LTD: OPERATING SEGMENTS
TABLE 91.LUPIN LTD: PRODUCT PORTFOLIO
TABLE 92.LUPIN LTD: NET SALES
TABLE 93.LUPIN LTD: KEY STRATERGIES
TABLE 94.MACLEODS PHARMACEUTICALS LTD: COMPANY SNAPSHOT
TABLE 95.MACLEODS PHARMACEUTICALS LTD: OPERATING SEGMENTS
TABLE 96.MACLEODS PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
TABLE 97.MACLEODS PHARMACEUTICALS LTD: NET SALES
TABLE 98.MACLEODS PHARMACEUTICALS LTD: KEY STRATERGIES
TABLE 99.MERCK KGAA: COMPANY SNAPSHOT
TABLE 100.MERCK KGAA: OPERATING SEGMENTS
TABLE 101.MERCK KGAA: PRODUCT PORTFOLIO
TABLE 102.MERCK KGAA: NET SALES
TABLE 103.MERCK KGAA: KEY STRATERGIES
TABLE 104.PFIZER INC.: COMPANY SNAPSHOT
TABLE 105.PFIZER INC.: OPERATING SEGMENTS
TABLE 106.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 107.PFIZER INC.: NET SALES
TABLE 108.PFIZER INC.: KEY STRATERGIES
TABLE 109.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 110.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 111.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 112.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES
TABLE 113.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
